This is a randomised controlled trial of Meropenem versus Piperacillin-Tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible escherichia coli and klebsiella spp. This study aims to determine which treatment is preferable for emerging resistant pathogens causing blood stream infections.
Australiasian Society for Infectious Diseases Clinical Trials Research Network
National Health & Medical Research Council
Prof Monica Slavin, Head of Infectious Diseases and Infection Control
Dr Abby Douglas
Infectious Diseases Registrar
Email: [email protected]